• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, May 30

MARS Therapeutics & Chemicals Ltd has announced the launch of its first European research molecule — Doxofylline— useful in the treatment of asthma and respiratory problems in India. Doxofylline, a new generation methylxanthine has been introduced by the Hyderabad-based company under the brand name Oxypur in 400 mg dosage, according to a press release. MARS has the sole manufacturing license in India under the agreement with Kent Union Ltd, Hong Kong & marketing cooperation of Eurodrug Laboratories, Belgium. The company is manufacturing under an exclusive agreement for Doxofylline formulations for Dr Reddy's Laboratories and Ranbaxy Laboratories Ltd, the release said.

More Stories on : Announcements | New Products & Services | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
REL seeks to ensure gas supply from KG Basin

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line